Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model.
Animals
Anti-Bacterial Agents
/ therapeutic use
Cystic Fibrosis
/ complications
Disease Models, Animal
Embryo, Nonmammalian
/ immunology
Mice
Pseudomonas Infections
/ immunology
Pseudomonas Phages
/ growth & development
Pseudomonas aeruginosa
/ isolation & purification
Respiratory Tract Infections
/ microbiology
Zebrafish
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 02 2019
06 02 2019
Historique:
received:
08
08
2018
accepted:
11
12
2018
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
1
9
2020
Statut:
epublish
Résumé
Cystic fibrosis (CF) is a hereditary disease due to mutations in the CFTR gene and causes mortality in humans mainly due to respiratory infections caused by Pseudomonas aeruginosa. In a previous work we used phage therapy, which is a treatment with a mix of phages, to actively counteract acute P. aeruginosa infections in mice and Galleria mellonella larvae. In this work we apply phage therapy to the treatment of P. aeruginosa PAO1 infections in a CF zebrafish model. The structure of the CFTR channel is evolutionary conserved between fish and mammals and cftr-loss-of-function zebrafish embryos show a phenotype that recapitulates the human disease, in particular with destruction of the pancreas. We show that phage therapy is able to decrease lethality, bacterial burden, and the pro-inflammatory response caused by PAO1 infection. In addition, phage administration relieves the constitutive inflammatory state of CF embryos. To our knowledge, this is the first time that phage therapy is used to cure P. aeruginosa infections in a CF animal model. We also find that the curative effect against PAO1 infections is improved by combining phages and antibiotic treatments, opening a useful therapeutic approach that could reduce antibiotic doses and time of administration.
Identifiants
pubmed: 30728389
doi: 10.1038/s41598-018-37636-x
pii: 10.1038/s41598-018-37636-x
pmc: PMC6365511
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1527Références
Development. 2013 Apr;140(8):1703-12
pubmed: 23487313
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
Methods Cell Biol. 2011;105:87-116
pubmed: 21951527
Dev Biol. 2015 Mar 15;399(2):237-48
pubmed: 25592226
Transplant Proc. 2006 Jan-Feb;38(1):331-3
pubmed: 16504739
Reprod Toxicol. 2012 Apr;33(2):128-32
pubmed: 21726626
Cell. 2017 Mar 23;169(1):85-95.e8
pubmed: 28340353
Am J Respir Cell Mol Biol. 2007 Jan;36(1):1-7
pubmed: 16888286
Adv Exp Med Biol. 2012;946:253-75
pubmed: 21948373
Science. 1989 Sep 8;245(4922):1066-73
pubmed: 2475911
Methods Mol Biol. 2014;1149:709-21
pubmed: 24818945
J Clin Invest. 2010 Sep;120(9):3149-60
pubmed: 20739752
J Infect Dis. 2010 Apr 1;201(7):1096-104
pubmed: 20196657
Biomed Res Int. 2016;2016:5258727
pubmed: 27340661
Respir Res. 2009 Mar 13;10:23
pubmed: 19284656
J Bacteriol. 2010 Feb;192(4):1113-21
pubmed: 20023018
Bacteriophage. 2011 Mar;1(2):111-114
pubmed: 22334867
Antimicrob Agents Chemother. 2018 May 25;62(6):
pubmed: 29555626
Emerg Top Life Sci. 2017 Apr 21;1(1):93-103
pubmed: 33525818
Cell Microbiol. 2009 May;11(5):755-68
pubmed: 19207728
Cell Microbiol. 2009 Feb;11(2):208-16
pubmed: 19068098
J Fish Dis. 2017 Jun;40(6):841-846
pubmed: 27454188
PLoS One. 2012;7(10):e47742
pubmed: 23082205
BMC Dev Biol. 2008 Mar 10;8:27
pubmed: 18331627
Microb Pathog. 2016 Oct;99:68-77
pubmed: 27498362
Crit Care. 2017 Jun 4;21(1):129
pubmed: 28583189
J Infect Dis. 2017 Mar 1;215(5):703-712
pubmed: 28007922
Crit Care. 2016 Jun 22;20(1):136
pubmed: 27329228
J Microbiol Methods. 2015 Oct;117:85-94
pubmed: 26188283
Infect Immun. 2010 Nov;78(11):4542-50
pubmed: 20732993
J Allergy Clin Immunol. 1999 Jul;104(1):72-8
pubmed: 10400842
Clin Chest Med. 2016 Mar;37(1):17-29
pubmed: 26857765
Transplant Proc. 2003 Sep;35(6):2372-3
pubmed: 14529945
mBio. 2012 Mar 06;3(2):e00029-12
pubmed: 22396480
Blood. 2011 Jan 27;117(4):e49-56
pubmed: 21084707
Crit Care Med. 2015 Jun;43(6):e190-8
pubmed: 25803649
Sci Rep. 2016 May 26;6:26717
pubmed: 27225966
J Interferon Cytokine Res. 2013 Mar;33(3):121-9
pubmed: 23289731
Biomed Res Int. 2015;2015:752930
pubmed: 25879036
Dis Model Mech. 2012 Jan;5(1):38-47
pubmed: 22228790
Nat Protoc. 2008;3(1):59-69
pubmed: 18193022
Mol Microbiol. 1992 Nov;6(22):3405-13
pubmed: 1484492
N Engl J Med. 2015 Jan 22;372(4):351-62
pubmed: 25607428
Respirology. 2015 May;20(4):569-78
pubmed: 25823858
Infect Immun. 2009 Apr;77(4):1293-303
pubmed: 19168742
Science. 2008 Sep 26;321(5897):1837-41
pubmed: 18818360
Cell Death Dis. 2018 Feb 15;9(3):275
pubmed: 29449653
Immunity. 2004 Apr;20(4):367-79
pubmed: 15084267
Curr Opin Pulm Med. 2011 Nov;17(6):478-83
pubmed: 21857224
Pharm Res. 2015 Jul;32(7):2173-9
pubmed: 25585954
Sci Rep. 2014 Oct 17;4:6653
pubmed: 25323747
Nature. 1992 Sep 17;359(6392):211-5
pubmed: 1382232
Angiogenesis. 2017 May;20(2):245-267
pubmed: 28378227
Environ Microbiol. 2015 Nov;17(11):4379-93
pubmed: 25845292
Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S39-56
pubmed: 26335954
Nat Rev Microbiol. 2010 May;8(5):317-27
pubmed: 20348932
Nat Protoc. 2013 Jun;8(6):1114-24
pubmed: 23680983